February 20, 2026
Protagonist Therapeutics' execs discuss their oral peptide platform, with two drugs at the FDA, and a pipeline targeting obesity and I&I.
February 19, 2026
NewLimit is pioneering epigenetic reprogramming to make old cells function like young ones again, developing novel therapies for age-related diseases.
February 18, 2026
Gordian Biotech is using its high-throughput in vivo screening platform to help Pfizer discover new obesity targets, revolutionizing discovery.
February 17, 2026
Ocular Therapeutix's AXPAXLI is the first drug to prove superiority over EYLEA in a landmark Phase 3 trial for wet AMD.
Infinitopes raises $15.4M, totaling $35.1M for its novel cancer vaccine. Clinical data on its unique immunopeptidomics tech is due by EOY.
February 13, 2026
Biotech CEOs discuss a patient-centric approach, navigating policy and funding, and the need for collaboration to maintain global leadership.
February 12, 2026
Mizuho's Graig Suvannavejh on key biotech readouts: Ideaya in uveal melanoma, EyePoint in wet AMD, Palvella in rare skin disease & Corvus.
February 11, 2026
Upstream Bio's verekitug shows strong Ph2 asthma data with 12-week dosing, but market reacts negatively to 24-week results. CEO discusses path to Ph3.
January 28, 2026
Corvus Pharma CEO discusses soquelitinib's promising atopic dermatitis data, highlighting its novel ITK inhibitor mechanism and durable effects.
January 17, 2026
Top biotech investor Joe Edelman shares his objective, probability-based investment philosophy, his bullish outlook for 2026, and key holdings.
January 16, 2026
Cytokinetics' CEO discusses the launch of its cardiomyopathy drug MYQORZO, aiming to outcompete BMS with a differentiated, lighter REMS.
Sana Bio's CEO details a potential cure for type 1 diabetes using gene-edited, immune-evasive stem cell-derived islets to end insulin need.
January 15, 2026
Neurocrine Biosciences' CEO discusses a strategy of leveraging core biology for new areas like obesity and advancing a selective M4 agonist.
Recursion's new CEO Najat Khan shares her vision for leveraging an end-to-end AI platform to deliver differentiated medicines at scale.
Astellas CEO outlines its strategy: leveraging a biology-first R&D approach and key assets to drive growth and offset the 2027 Xtandi patent cliff.
January 12, 2026
Beam Therapeutics' CEO discusses an accelerated FDA pathway for its alpha-1 base editor, a planned BLA filing for its sickle cell therapy, and future platform expansion.
Vera Therapeutics' atacicept for IgA Nephropathy gets FDA priority review. With strong Phase 3 data, the company prepares for a July US launch.
January 7, 2026
Mizuho's Salim Syed on key biotech catalysts: Eyes on BridgeBio's launch, Cytokinetics' data, Vaxite's macro shift, and Biogen/Arcus value.
December 30, 2025
The obesity drug market heats up as Novo's oral Wegovy challenges injectables, but its strict dosing regimen may cede ground to Lilly's orfoglipron.
December 29, 2025
Deep dive on Abivax: Analyst Gregory Renza discusses the upcoming maintenance trial, Obafazimod's risks, and intense M&A speculation.
December 12, 2025
Create Medicines engineers myeloid, T, & NK cells in vivo using a versatile LNP/RNA platform, enabling repeat dosing for solid tumors and beyond.
December 11, 2025
LabGenius uses ML to design safer, non-intuitive multi-specific antibodies, partnering with Sanofi and advancing its lead Nectin-4 candidate.
Medra raised $52M to build "physical AI scientists," combining AI reasoning with adaptive robotics to automate and scale scientific discovery.
December 9, 2025
Colonia Therapeutics' in vivo CAR-T shows deep MRD-negative responses in myeloma without chemo, a potential paradigm shift in cancer therapy.
Corvus Pharma's ITK inhibitor, soquelitinib, shows a remarkable 28-month survival in T-cell lymphoma and is expanding into atopic dermatitis.
December 8, 2025
Neurix's BTK degrader shows 22.1-month PFS in late-line CLL. CEO discusses strategy for degraders to displace inhibitors across medicine.
December 7, 2025
Orca Bio's Orca T therapy aims to replace stem cell transplants for blood cancer, using regulatory T-cells to prevent GVHD. PDUFA is April 6.
December 5, 2025
Vi Ventures is launching a new fund for the I&I revolution, leveraging a unique model of partnering with patient foundations to de-risk drug development.
December 4, 2025
Accession Therapeutics tackles solid tumors with armed, de-targeted viruses that deliver potent drugs locally, avoiding systemic toxicity.
November 19, 2025
Ipsen's CEO discusses a growth strategy fueled by neurotoxin innovation, rare disease drug expansion, and over €3B for M&A in oncology.
Terns Pharmaceuticals' TURNS-701 shows 'best in disease' potential for CML with an unprecedented 64% MMR rate and superior safety profile.
Investor Patrick Nosker on biotech's recovery: M&A will continue, driven by pharma needs. Key insights on Xenon, Madrigal, and Alkermes.
November 18, 2025
Jefferies' Philip Ross on biotech: M&A thrives on pharma's growth needs, but P&L capacity, not cash, is the real constraint. Outlook is bullish.
GSK's CSO Tony Wood outlines their R&D strategy: rebuilding oncology, innovating with long-acting antibodies, and targeted bolt-on acquisitions.
Protagonist Therapeutics' CEO on M&A buzz, lucrative J&J/Takeda deals, and a new oral triple-agonist for the competitive obesity market.
November 17, 2025
Biopharma M&A is booming, driven by pharma's patent cliffs. Expect more large deals in 2026, fueling capital recycling & industry growth.
November 13, 2025
Legend Biotech opens a new Philly R&D lab, boosts manufacturing to 10k doses/yr, and celebrates 2nd-line CARVICTI approval in US/EU.
November 12, 2025
Apogee Therapeutics is developing extended half-life antibodies for I&I diseases, aiming to shift dosing from bi-weekly to quarterly or longer.
November 11, 2025
Cellcuity's gadotolitinib shows historic efficacy in hard-to-treat wild-type HR+/HER2- breast cancer by comprehensively inhibiting the PAM pathway.
Aardvark Therapeutics targets hunger via a novel gut-brain signaling drug, advancing a Phase 3 trial for Prader-Willi syndrome due in '26.
November 10, 2025
Adaptix is creating a wearable biosensor patch for continuous, real-time biochemical monitoring, set to revolutionize clinical care and wellness.
November 8, 2025
Synthakyne's alpha-beta biased IL-2 shows >50% response rate in hard-to-treat lung cancer, promising a safer, more targeted IO therapy.
November 5, 2025
Healthcare's AI boom: A new report reveals surprisingly fast adoption, driven by organic need, with startups outmaneuvering incumbents.
November 4, 2025
Arthex Biotech is developing ATX01 for Myotonic Dystrophy Type 1, using a novel dual-action RNA approach to target both muscle and CNS.
Step Pharma pioneers a first-in-class CTPS1 inhibitor for oncology, leveraging synthetic lethality for a targeted, safe therapeutic approach.
November 3, 2025
Repro Novo is advancing two Phase 2 assets in reproductive health for male infertility and adenomyosis, funded by a $65M Series A.